Federated Investors Inc. PA lessened its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 20.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 349,381 shares of the medical research company’s stock after selling 87,458 shares during the period. Federated Investors Inc. PA’s holdings in PRA Health Sciences were worth $32,618,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PRAH. BlackRock Inc. raised its position in PRA Health Sciences by 27.2% in the 2nd quarter. BlackRock Inc. now owns 5,426,909 shares of the medical research company’s stock worth $506,656,000 after purchasing an additional 1,159,446 shares during the last quarter. FMR LLC raised its position in PRA Health Sciences by 84.6% in the 2nd quarter. FMR LLC now owns 2,295,675 shares of the medical research company’s stock worth $214,324,000 after purchasing an additional 1,051,810 shares during the last quarter. Bank of New York Mellon Corp raised its position in PRA Health Sciences by 44.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,197,004 shares of the medical research company’s stock worth $205,113,000 after purchasing an additional 673,202 shares during the last quarter. Jennison Associates LLC raised its position in PRA Health Sciences by 4,357.1% in the 2nd quarter. Jennison Associates LLC now owns 625,994 shares of the medical research company’s stock worth $58,443,000 after purchasing an additional 611,949 shares during the last quarter. Finally, Bellevue Group AG bought a new position in PRA Health Sciences in the 2nd quarter worth approximately $12,081,000. Hedge funds and other institutional investors own 98.82% of the company’s stock.

Shares of PRA Health Sciences stock opened at $105.01 on Friday. The firm has a market cap of $6.85 billion, a price-to-earnings ratio of 32.82, a price-to-earnings-growth ratio of 1.61 and a beta of 0.54. PRA Health Sciences Inc has a 52 week low of $73.23 and a 52 week high of $108.02. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.93 and a quick ratio of 0.93.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, August 1st. The medical research company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.88 by $0.12. The company had revenue of $722.84 million during the quarter, compared to analysts’ expectations of $706.57 million. PRA Health Sciences had a net margin of 4.25% and a return on equity of 24.52%. The business’s revenue for the quarter was up 35.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS. sell-side analysts forecast that PRA Health Sciences Inc will post 3.89 EPS for the current year.

In other PRA Health Sciences news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $101.01, for a total transaction of $656,565,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Several research analysts recently weighed in on the stock. KeyCorp restated a “buy” rating and issued a $115.00 price objective on shares of PRA Health Sciences in a research report on Thursday, August 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $115.00 target price on shares of PRA Health Sciences in a research report on Friday, July 20th. Credit Suisse Group upped their target price on shares of PRA Health Sciences from $104.00 to $107.00 and gave the company an “outperform” rating in a research report on Thursday, August 2nd. SunTrust Banks upped their target price on shares of PRA Health Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Finally, Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a research report on Tuesday, July 3rd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Buy” and an average price target of $107.00.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.